Document Detail


Combined modality therapy including surgery for stage III small-cell lung cancer on the basis of the sensitivity assay in vitro.
MedLine Citation:
PMID:  10664334     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifty-nine consecutive patients with clinical stage (cStage) I-III resectable small-cell lung cancer (SCLC) underwent surgery with adjuvant chemotherapy based on an in vitro sensitivity assay between April 1982 and March 1992. In 42 (71%) of these patients, a stable passage of cancer cells from resected specimens was possible and the sensitivity of these cultured SCLC cells to anticancer drugs was examined by the MTT method. In the sensitivity assay, vincristine (VCR) showed the most intense specific efficacy for SCLC, followed by cyclophosphamide (CPM) and cisplatin (CDDP). The 5-year survival rates for pathological stage (pStage) I, pStage II, and pStage III were 55%, 33%, and 23%, respectively. The 5-year survival of the patients with pStage III operated on in the first 5 years was 7% (1/14). On the other hand, 6 of the 16 pStage III patients (38%) operated on during the second 5-year period, who were generally treated with pre- and postoperative adjuvant chemotherapy combined with three drugs, survived over 5 years. In conclusion, these results suggest that combined modality therapy including surgery is necessary, and adjuvant chemotherapy combined with VCR, CPM, and CDDP may be useful in the treatment of Stage III SCLC disease, for the purpose of achieving a long-term survival with both a good performance status and quality of life for the patients.
Authors:
S Kobayashi; S Okada; T Hasumi; N Sato; S Fujimura
Related Documents :
21737654 - Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneo...
9154094 - Lung cancer.
2539294 - Three-year disease-free survivors of small cell lung cancer treated with combination ch...
19458554 - Results of surgical treatment for patients with small cell lung cancer.
3839844 - Stage iii hodgkin's disease: improved survival with combined modality therapy as compar...
11383814 - Evolving management and outcome of esophageal cancer with airway involvement.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Surgery today     Volume:  30     ISSN:  0941-1291     ISO Abbreviation:  Surg. Today     Publication Date:  2000  
Date Detail:
Created Date:  2000-04-12     Completed Date:  2000-04-12     Revised Date:  2006-08-03    
Medline Journal Info:
Nlm Unique ID:  9204360     Medline TA:  Surg Today     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  127-33     Citation Subset:  IM    
Affiliation:
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-77, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Small Cell / mortality,  pathology,  therapy*
Combined Modality Therapy
Drug Screening Assays, Antitumor
Female
Humans
Lung Neoplasms / mortality,  pathology,  therapy*
Male
Middle Aged
Neoplasm Staging
Pneumonectomy*
Retrospective Studies
Survival Rate
Thoracotomy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery.
Next Document:  Completion pneumonectomy for patients with recurrent lung cancer: the impact of microvessel density ...